Skip to main content
Figure 2 | Clinical and Translational Medicine

Figure 2

From: Fractalkine (CX3CL1), GM-CSF and VEGF-a levels are reduced by statins in adult patients

Figure 2

Effect of HMG-CoA reductase inhibitors on fractalkine (CX3CL1) plasma levels in adult human subjects. Levels of Fractalkine (CX3CL1) were determined in plasma of adult human subjects (n = 12) without known coronary artery disease after no therapy (None), Atorvastatin 80 mg daily, Pravastatin 80 mg daily, or Rosuvastatin 10 mg daily for two weeks. Results shown are the mean values and error bars indicate standard error of the mean. * indicate significant differences versus no statin therapy, p ≤ 0.001.

Back to article page